GM-CSF and low-dose araC treatment of AML in prolonged hypoplasia with residual leukemic cells after induction chemotherapy.
- Author:
Yoo Hong MIN
1
;
Sung Eun KIM
;
Seung Tae LEE
;
Sun Ju LEE
;
Jee Sook HAHN
;
Yun Woong KO
Author Information
- Publication Type:Case Report
- Keywords: Acute myelogenous leukemia GM-CSF; low-dose Ara-C
- MeSH: Bone Marrow Diseases/chemically induced/*drug therapy; Case Report; Cytarabine/*administration & dosage; Granulocyte-Macrophage Colony-Stimulating Factor/*therapeutic use; Human; Leukemia, Myelocytic, Acute/*drug therapy/pathology; Male; Middle Age
- From:Yonsei Medical Journal 1994;35(1):91-96
- CountryRepublic of Korea
- Language:English
- Abstract: We describe a case with acute myelogenous leukemia (AML; M2) who developed prolonged marrow hypoplasia with residual leukemic blasts and recurrent infections after induction chemotherapy. He was treated successfully with a sequential treatment of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and low-dose cytosine arabinoside (LD AraC). To the best of our knowledge this is the first reported case of a successful treatment of a patient with AML, who showed prolonged markedly hypocellular bone marrow with significant residual leukemic cells after induction chemotherapy, with a sequential treatment of GM-CSF and LD AraC.
